The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

CHK1 inhibitor + rheumatoid arthritis drug could be therapy for NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute researchers have found a potentially effective drug-combination approach to treating certain patients with non-small cell lung cancer. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Researchers explore adapted Argentine tango dance therapy for cancer survivors at Ohio State

Adapted Argentine tango dance therapy is helping some breast cancer survivors regain natural balance and sensation after experiencing neuropathy, a common side effect of chemotherapy treatment. Expansion of a new clinical study will look further at how this musical movement intervention can “rewire” the brain to improve function after chemotherapy-related nerve changes.
Clinical Roundup

Investigational therapy shrinks drug-resistant NSCLC by activating NK cells, study finds

An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging an attack from natural killer cells in an animal model, a study led by UT Southwestern Medical Center researchers shows. The findings, published in the Journal for ImmunoTherapy of Cancer, could lead to new types of immunotherapy that rely on this novel strategy.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account